Last week, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced it will no longer require nor accept applications for the DATA 2000 Waiver previously needed to prescribe the drug most frequently used for the treatment of opioid use disorder (OUD). All practitioners with a current DEA registration that includes prescribing authority for Schedule III substances may now prescribe buprenorphine for OUD if permitted in the state where they practice. The change comes from Section 1262 of the Consolidated Appropriations Act, 2023, which removes the federal requirement for practitioners to submit a Notice of Intent to prescribe medications for the treatment of OUD.